



Funding for Pediatric TB Research, 2012


*Supplement to the 2013 Report on Tuberculosis
Research Funding Trends, 2005–2012*

BY ERICA LESSEM AND ELEONORA JIMÉNEZ-LEVI

With support from the TB Alliance

Pediatric TB R&D Investments by Research Category

2012 Total: \$10,278,875



2012 Pediatric TB R&D Funders by Rank and Compared with Prior Years

2012 Rank	Funding Organization	Funder Type	2012 Pediatric TB R&D Funding	2011 Pediatric TB R&D Funding	2010 Pediatric TB R&D Funding	2012 Total TB R&D Funding	Percentage of 2012 Total R&D Funding Allocated to Pediatrics
1	U.K. Medical Research Council	P	\$2,644,610	\$3,111,533	\$408,718	\$14,790,087	17.9
3	Other National Institutes of Health Institutes and Centers*	P	\$2,624,745	\$1,917,849	\$1,772,537	\$36,646,883	7.2
3	Company X	C	\$1,718,595	N/A	N/A	\$22,844,099	7.5
4	U.S. National Institute of Allergy and Infectious Diseases*	P	\$954,061	\$532,394	\$554,003	\$169,092,971	0.6
5	Wellcome Trust	F	\$551,017	\$2,606,924	\$322,682	\$13,418,817	4.1
6	Company V	C	\$481,080	N/A	N/A	\$4,297,934	11.2
13	U.S. President's Emergency Plan for AIDS Relief	P	\$450,000	\$0	\$0	\$6,606,609	6.8

P= public-sector R&D agency; C= Corporation/private sector; M= Multilateral; F=Foundation/philanthropy; P-D= Public-sector development agency

*TAG reports National Institutes of Health investments in three categories: 1) National Institute of Allergy and Infectious Diseases—the largest investor in TB R&D overall; 2) the National Health, Lung and Blood Institute—which did not document investments in pediatric TB R&D; and 3) other NIH institutes and centers.

Note: This table records contributions made only by funders investing in pediatric TB R&D in 2012.

2012 Pediatric TB R&D Funders by Rank and Compared with Prior Years (continued)

2012 Rank	Funding Organization	Funder Type	2012 Pediatric TB R&D Funding	2011 Pediatric TB R&D Funding	2010 Pediatric TB R&D Funding	2012 Total TB R&D Funding	Percentage of 2012 Total R&D Funding Allocated to Pediatrics
8	Canadian Institutes of Health Research	P	\$326,268	\$661,616	N/A	\$6,017,561	5.4
9	Australian National Health and Medical Research Council	P	\$166,738	\$295,363	\$153,590	\$4,060,791	4.1
10	Danish International Development Agency	P-D	\$154,993	N/A	N/A	\$323,250	47.9
11	World Health Organization	M	\$85,260	\$0	\$0	\$1,707,923	5.0
12	U.S. Agency for International Development	P-D	\$50,000	N/A	N/A	\$12,174,064	0.4
13	Norwegian Knowledge Centre for the Health Services	P	\$48,460	N/A	N/A	\$48,460	100.0
14	Indian Council of Medical Research	P	\$23,047	N/A	N/A	\$7,131,390	0.3
Grand Total			\$10,278,875				

P= public-sector R&D agency; C= Corporation/private sector; M= Multilateral; F=Foundation/philanthropy; P-D= Public-sector development agency

*TAG reports National Institutes of Health investments in three categories: 1) National Institute of Allergy and Infectious Diseases—the largest investor in TB R&D overall; 2) the National Health, Lung and Blood Institute—which did not document investments in pediatric TB R&D; and 3) other NIH institutes and centers.

Note: This table records contributions made only by funders investing in pediatric TB R&D in 2012.